ADVFN Logo ADVFN

Wir konnten keine Ergebnisse für:
Stelle sicher, dass deine Schreibweise korrekt ist oder versuche deine Suche zu erweitern.

Trends

Toplisten

Es scheint, dass du nicht eingeloggt bist.
Klicke auf den Button unten, um dich einzuloggen und deine zuletzt angesehenen Aktien zu sehen.

Hot Features

Registration Strip Icon for charts Registrieren Sie sich für Echtzeit-Charts, Analysetools und Preise.

AMRN Amarin Corp PLC

0,9289
0,0519 (5,92%)
01 Mai 2024 - Geschlossen
Verzögert um 15 Minuten
Name Symbol Markt Aktientyp
Amarin Corp PLC AMRN NASDAQ Depository Receipt
  Änderung Änderung % Aktuell Zeit
0,0519 5,92% 0,9289 02:00:00
Handelsbeginn Niedrig Hoch Schlusskurs Handelsende
0,884 0,8692 0,9289 0,9209 0,877
more quote information »

Aktuelle News

Datum Zeit Quelle Überschrift
24.4.202420:00GLOBEAmarin Applauds HealthyWomen’s Citizen’s Petition Urging FDA..
22.4.202414:00GLOBEAmarin Announces Results of Annual General Meeting of..
15.4.202414:00GLOBEAmarin to Report First Quarter 2024 Financial Results and..
08.4.202414:00GLOBEAmarin Highlights Key Data Providing Mechanistic Insights..
08.4.202412:30PRNCANew REDUCE-IT® Analyses Show VASCEPA® (Icosapent Ethyl)..
06.4.202421:30GLOBENew REDUCE-IT® Analyses Show VASCEPA®/VAZKEPA® (Icosapent..
03.4.202414:00GLOBEAmarin Provides Update on VAZKEPA® (Icosapent Ethyl)..
25.3.202413:00GLOBEResearch Evaluating Benefits of VASCEPA®/VAZKEPA® (icosapent..
04.3.202423:30EDGAR2Form ARS - Annual Report to Security Holders
04.3.202414:00EDGAR2Form DEF 14A - Other definitive proxy statements
29.2.202413:06EDGAR2Form 10-K - Annual report [Section 13 and 15(d), not S-K..
29.2.202413:05EDGAR2Form 8-K - Current report
29.2.202413:00GLOBEAmarin Reports Fourth Quarter and Full Year 2023 Financial..
15.2.202414:00GLOBEAmarin to Report Fourth Quarter and Full Year 2023 Financial..
12.2.202414:00EDGAR2Form PRE 14A - Other preliminary proxy statements
09.2.202422:31EDGAR2Form 4 - Statement of changes in beneficial ownership of..
09.2.202422:30EDGAR2Form 4 - Statement of changes in beneficial ownership of..
09.2.202422:30EDGAR2Form 4 - Statement of changes in beneficial ownership of..
02.2.202422:30EDGAR2Form 4 - Statement of changes in beneficial ownership of..
02.2.202422:30EDGAR2Form 4 - Statement of changes in beneficial ownership of..
02.2.202422:30EDGAR2Form 4 - Statement of changes in beneficial ownership of..
26.1.202413:00EDGAR2Form 8-K - Current report
24.1.202422:31EDGAR2Form 4 - Statement of changes in beneficial ownership of..
22.1.202413:30GLOBEAmarin Chairman & CEO Issue Letter to Shareholders
12.1.202423:31EDGAR2Form 4 - Statement of changes in beneficial ownership of..
12.1.202423:27EDGAR2Form 4 - Statement of changes in beneficial ownership of..
12.1.202423:25EDGAR2Form 4 - Statement of changes in beneficial ownership of..
10.1.202413:00EDGAR2Form 8-K - Current report
10.1.202413:00GLOBEAmarin Provides Preliminary Fourth Quarter 2023 Selected..
09.1.202400:03EDGAR2Form 4 - Statement of changes in beneficial ownership of..
09.1.202400:03EDGAR2Form 4 - Statement of changes in beneficial ownership of..
02.1.202422:47EDGAR2Form 4 - Statement of changes in beneficial ownership of..
02.1.202422:43EDGAR2Form 4 - Statement of changes in beneficial ownership of..
15.12.202300:35EDGAR2Form 4 - Statement of changes in beneficial ownership of..
12.12.202322:20EDGAR2Form 144 - Report of proposed sale of securities
11.12.202314:00GLOBEAmarin to Present at the 42nd Annual J.P. Morgan Healthcare..
05.12.202322:30EDGAR2Form 4 - Statement of changes in beneficial ownership of..
05.12.202313:30EDGAR2Form SC 13D/A - General statement of acquisition of..
12.11.202315:00GLOBENew REDUCE-IT® Analyses Show VASCEPA® (icosapent ethyl)..
03.11.202321:30EDGAR2Form 8-K - Current report
01.11.202312:05EDGAR2Form 8-K - Current report
01.11.202312:05EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
01.11.202312:00GLOBEAmarin Reports Third Quarter 2023 Financial Results
31.10.202321:05EDGAR2Form 8-K - Current report
31.10.202317:00GLOBEAmarin Appoints Jonathan Provoost Executive Vice President,..
26.10.202314:00GLOBELatest Research Evaluating VASCEPA®/VAZKEPA® (icosapent..
19.10.202314:00GLOBE Amarin to Report Third Quarter 2023 Financial Results and..
12.9.202314:00GLOBEAmarin to Present at the 2023 Cantor Global Healthcare..
05.9.202322:15EDGAR2Form SC 13D/A - General statement of acquisition of..
17.8.202301:51EDGAR2Form 4 - Statement of changes in beneficial ownership of..

Kürzlich von Ihnen besucht

Delayed Upgrade Clock